Semaglutide Effects on Insulin Sensitivity and Cardiometabolic Risk Factors

Study of semaglutide effects on insulin sensitivity and cardiometabolic risk factors confirms improvements across multiple metabolic parameters during weight management.

Arslanian, Silva et al.·Diabetes care·2025·Strong EvidenceRCT
RPEP-09990RCTStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
RCT
Evidence
Strong Evidence
Sample
N=not specified
Participants
Adolescents aged 12 to <18 years with obesity

What This Study Found

Study of semaglutide effects on insulin sensitivity and cardiometabolic risk factors confirms improvements across multiple metabolic parameters during weight management.

Key Numbers

Adolescents aged 12 to <18. Semaglutide 2.4 mg weekly vs. placebo. Estimated BMI difference: -16.7% at week 68.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Study of semaglutide effects on insulin sensitivity and cardiometabolic risk factors confirms improv
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.
Published In:
Diabetes care (2025)
Database ID:
RPEP-09990

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Study of semaglutide effects on insulin sensitivity and cardiometabolic risk factors confirms improvements across multiple metabolic parameters during weight management.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09990·https://rethinkpeptides.com/research/RPEP-09990

APA

Arslanian, Silva; Gies, Inge; Goldman, Bryan; Karlsson, Tobias; Kelly, Aaron S; Skalshøi Kjær, Mette; Körner, Antje; Noureddin, Mazen; Wabitsch, Martin; Harder-Lauridsen, Nina M; Weghuber, Daniel. (2025). Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.. Diabetes care. https://doi.org/10.2337/dc25-0824

MLA

Arslanian, Silva, et al. "Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.." Diabetes care, 2025. https://doi.org/10.2337/dc25-0824

RethinkPeptides

RethinkPeptides Research Database. "Effect of Semaglutide on Insulin Sensitivity and Cardiometab..." RPEP-09990. Retrieved from https://rethinkpeptides.com/research/arslanian-2025-effect-of-semaglutide-on

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.